# Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

> **NCT01066195** · PHASE3 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 129 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** iressa
- **DRUG:** alimta

## Key facts

- **NCT ID:** NCT01066195
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-05
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2010-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01066195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01066195, "Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01066195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*